CHMP denies Novartis heart failure drug PMLiVE The Committee for Medicinal Products for Human Use (CHMP), which provides guidance on drugs for the European Medicines Agency (EMA), said it was unable to back the drug as a treatment for the symptoms of acute heart failure based data provided by ... |
